The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
{{output}}
Background: Nivolumab, a human immunoglobulin IgG4 monoclonal antibody targeting PD-1 receptor, received initial FDA approval in 2014 for treating unresectable or metastatic malignant melanoma (MM), followed by approval for metas... ...
